The Impact of Melphalan Conditioning and CD34 + Cell Dose and Schedule on Post‐Transplant Outcomes in AL Amyloidosis
American Journal of Hematology · 2025-07 · 100 (7) · 1141-1151
DOI: 10.1002/ajh.27685 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 11.04.2025. Verfasst von Eli Muchtar und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Melphalan, Transplantation Conditioning, Immunoglobulin Light-chain Amyloidosis, Antigens, CD34. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Mayo Clinic Transplant Center Scholarly Award.
Abstract (Originalsprache)
The optimal conditioning schedule and CD34+ cell dose for autologous stem cell transplantation (ASCT) for AL amyloidosis is unknown. Patients ( n = 1704) who underwent ASCT for AL amyloidosis between 2003 and 2020 in 9 centers were included. Data on melphalan conditioning dose, number of conditioning days, whether a rest day between conditioning and stem cell infusion was given or not, and infused CD34 + cell dose were collected. Full‐dose melphalan (≥ 180 mg/m 2 ) was administered in 63.7% of the patients, and 80.4% had melphalan split into 2‐day conditioning. A rest day (day −1) between the conditioning regimen and stem cell infusion was provided in 52.5% of patients. The median infused CD34 + cell count was 4.7 × 10 6 /kg. An infused CD34 + cell count ≥ 4.5 × 10 6 /kg was associated with a shorter time to neutrophil and platelet engraftment. In a nominal regression analysis, full‐dose melphalan, 1‐day melphalan conditioning, and omitting a rest day between conditioning and stem cell infusion were independent predictors of post‐ASCT higher deep hematological response. The median follow‐up was 8.6 years, and 38% of patients died. Independent predictors of superior overall survival in multivariate Cox regression analysis included full‐dose melphalan, having no rest day, and infused CD34 + cells ≥ 4.5 × 10 6 /kg. Independent predictors of higher day‐100 transplant‐related mortality (TRM) in nominal logistic regression analysis included poorer performance status, NT‐proBNP/BNP ≥ 1800/400 pg/mL, serum albumin < 2.5 g/dL, CD34 + cells < 4.5 × 10 6 /kg, and not having a rest day. In conclusion, 1 day of melphalan conditioning and administration of CD34 + cells ≥ 4.5 × 10 6 /kg are recommended for ASCT in AL amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Section of Hematology and Oncology, Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
- Medical Department V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany.
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.
- Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Eli Muchtar, Vaishali Sanchorawala, Hamza Hassan, Ute Hegenbart, Hans C Lee, Muzaffar Qazilbash, Angela Dispenzieri, Rajshekhar Chakraborty, Hila Magen, Morie Gertz
Förderung
- NCI NIH HHS
- Mayo Clinic Transplant Center Scholarly Award
Zitieren
APA
Muchtar, E., Sanchorawala, V., Hassan, H., Hegenbart, U., Schönland, S., Lee, H. C., Qazilbash, M., Kin, A., Zonder, J., Jacob, E., Buadi, F., Dispenzieri, A., Dingli, D., Arai, S., Chin, M., Chakraborty, R., Lentzsch, S., Magen, H., Shkury, E., …, & Gertz, M. (2025). The Impact of Melphalan Conditioning and CD34 + Cell Dose and Schedule on Post‐Transplant Outcomes in AL Amyloidosis. American Journal of Hematology, 100(7), 1141-1151. https://doi.org/10.1002/ajh.27685
Vancouver
Muchtar E, Sanchorawala V, Hassan H, Hegenbart U, Schönland S, Lee HC, et al. The Impact of Melphalan Conditioning and CD34 + Cell Dose and Schedule on Post‐Transplant Outcomes in AL Amyloidosis. American Journal of Hematology. 2025;100(7):1141-1151. doi:10.1002/ajh.27685
BibTeX
@article{Muchtar2025,
author = {Muchtar, Eli and Sanchorawala, Vaishali and Hassan, Hamza and Hegenbart, Ute and Schönland, Stefan and Lee, Hans C and Qazilbash, Muzaffar and Kin, Andrew and Zonder, Jeffrey and Jacob, Eapen and Buadi, Francis and Dispenzieri, Angela and Dingli, David and Arai, Sally and Chin, Michelle and Chakraborty, Rajshekhar and Lentzsch, Suzanne and Magen, Hila and Shkury, Eden and Sarubbi, Caitlin and Landau, Heather and Gertz, Morie},
title = {The Impact of Melphalan Conditioning and CD34 + Cell Dose and Schedule on Post‐Transplant Outcomes in AL Amyloidosis},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {7},
pages = {1141--1151},
doi = {10.1002/ajh.27685}
}
EUVIMED